These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18161530)

  • 1. Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy.
    Skitzki JJ; Muhitch JB; Evans SS
    Immunol Invest; 2007; 36(5-6):807-27. PubMed ID: 18161530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically engineered T cells as adoptive immunotherapy of cancer.
    Ma Q; Gonzalo-Daganzo RM; Junghans RP
    Cancer Chemother Biol Response Modif; 2002; 20():315-41. PubMed ID: 12703212
    [No Abstract]   [Full Text] [Related]  

  • 4. [Application of gene therapy in tumor adoptive immunotherapy].
    Wang C; Zhao Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Apr; 25(2):482-6. PubMed ID: 18610648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer.
    Gomez GG; Hutchison RB; Kruse CA
    Cancer Treat Rev; 2001 Dec; 27(6):375-402. PubMed ID: 11908930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
    Besser MJ; Schallmach E; Oved K; Treves AJ; Markel G; Reiter Y; Schachter J
    Cytotherapy; 2009; 11(2):206-17. PubMed ID: 19148842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.
    Kohlmeyer J; Cron M; Landsberg J; Bald T; Renn M; Mikus S; Bondong S; Wikasari D; Gaffal E; Hartmann G; Tüting T
    Cancer Res; 2009 Aug; 69(15):6265-74. PubMed ID: 19622767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer.
    Chiriva-Internati M; Weidanz JA; Yu Y; Frezza EE; Jenkins MR; Kennedy RC; Cobos E; Kast WM
    J Immunother; 2008 Oct; 31(8):693-703. PubMed ID: 18779750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo kinetics of murine lymphoid cells: in relation to local adoptive cancer immunotherapy.
    Yamasaki N; Kan N; Inamoto T; Nakayama N; Nio Y; Hori T
    Nihon Geka Hokan; 1984 Jan; 53(1):67-78. PubMed ID: 6333856
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
    Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
    Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale production and characterization of novel CD4+ cytotoxic T cells with broad tumor specificity for immunotherapy.
    Jursik C; Prchal M; Grillari-Voglauer R; Drbal K; Fuertbauer E; Jungfer H; Albert WH; Steinhuber E; Hemetsberger T; Grillari J; Stockinger H; Katinger H
    Mol Cancer Res; 2009 Mar; 7(3):339-53. PubMed ID: 19240181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
    Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
    Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetically modified tumor-infiltrating lymphocytes for cancer therapy.
    Friedmann T
    Cancer Cells; 1991 Jul; 3(7):271-4. PubMed ID: 1911040
    [No Abstract]   [Full Text] [Related]  

  • 17. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma.
    Markel G; Cohen-Sinai T; Besser MJ; Oved K; Itzhaki O; Seidman R; Fridman E; Treves AJ; Keisari Y; Dotan Z; Ramon J; Schachter J
    Anticancer Res; 2009 Jan; 29(1):145-54. PubMed ID: 19331144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.
    Tamai H; Watanabe S; Zheng R; Deguchi K; Cohen PA; Koski GK; Shu S
    Clin Immunol; 2008 Apr; 127(1):66-77. PubMed ID: 18262845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.
    Dang Y; Disis ML
    Ann N Y Acad Sci; 2009 Sep; 1174():81-7. PubMed ID: 19769740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.